Semaglutide has already become more than just a “vanity drug.” Clinical trials like SUSTAIN-6 and FLOW have shown it can slash the risk of kidney disease, reduce major heart attacks, and even lower ...

The companies have been embroiled in a row about compounded GLP-1 drugs that escalated to a lawsuit last month. The legal action has now been dropped and the former adversaries have struck a deal that ...

After years of fighting over compounded weight loss drugs, Hims & Hers and Novo Nordisk are teaming up to sell Ozempic and Wegovy — a shift that could raise costs for patients.

A 2026 industry overview of the Direct Meds telehealth platform, including its compounded GLP-1 medication access model, pricing structure, delivery formats, consultation process, pharmacy sourcing, ...

Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely ...

Semaglutide's patent expiry in India could sharply reduce the cost of popular weight-loss and diabetes injections.

A blockbuster anti-obesity and diabetes drug could cost as little as $3 per month to manufacture once it goes off patent later this month, researchers said Friday, providing a major opportunity to ...

While the introduction of branded generics is likely to accelerate volumes for GLP-1 agonists, value growth may moderate because of price erosion.

Study says lowering the annual cost by 18% or making the current cash price available to all patients would make semaglutide cost-effective. HealthDay News — Lowering the annual cost of semaglutide by ...

The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to ...